Manuel Romero-Gómez-rekin lankidetzan egindako argitalpenak (35)

2024

  1. Advanced fibrosis associated with non-alcoholic steatohepatitis (NASH) in Spain: results of a Delphi study

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 337-346

  2. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease

    Gut, Vol. 73, Núm. 5, pp. 825-834

  3. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

    Hepatology, Vol. 79, Núm. 1, pp. 135-148

  4. The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis

    Journal of Gastroenterology

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. AEEH «Consensus about detection and referral of hidden prevalent liver diseases»

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 3, pp. 236-247

  3. Liver investigation: Testing marker utility in steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol

    Contemporary Clinical Trials, Vol. 134

  4. Predicting liver-related events in NAFLD: A predictive model

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 4, pp. 1240-1251

  5. Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD

    Liver International, Vol. 43, Núm. 9, pp. 1909-1919

2022

  1. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?

    Gut, Vol. 71, Núm. 2, pp. 382-390

  2. Dietary Recommendations for the Management of Non-alcoholic Fatty Liver Disease (NAFLD): A Nutritional Geometry Perspective

    Seminars in Liver Disease, Vol. 42, Núm. 4, pp. 434-445

  3. Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation

    Scientific Reports, Vol. 12, Núm. 1

  4. Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles

    Hepatology, Vol. 76, Núm. 4, pp. 1121-1134

  5. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

    Liver International, Vol. 42, Núm. 8, pp. 1783-1792

2021

  1. Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease

    EBioMedicine, Vol. 70

  2. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

  3. Impacto clínico y económico global de la enfermedad hepática por hígado graso no alcohólico

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 6, pp. 396-403

  4. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease

    Journal of Hepatology, Vol. 75, Núm. 4, pp. 786-794

  5. Mistranslation Drives Alterations in Protein Levels and the Effects of a Synonymous Variant at the Fibroblast Growth Factor 21 Locus

    Advanced Science, Vol. 8, Núm. 11

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5